August 5, 2025 — Leads & Copy — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on medicines for degenerative muscle diseases, will present at Canaccord Genuity’s 45th Annual Growth Conference, Aug. 13–14, at the InterContinental Boston.
Satellos management will present on Wed., Aug. 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will participate in one-on-one meetings during the conference.
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website, and a replay will be available following the presentation.
Satellos is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Its research has led to SAT-3247, an orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. SAT-3247 is in clinical development as a potential disease-modifying treatment, starting with DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit.
Source: Satellos Bioscience Inc.
